{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit number not reached","groupId":"OG000","lowerLimit":"29.0","upperLimit":"NA","value":"52.57"},{"comment":"upper limit number not reached","groupId":"OG001","lowerLimit":"13.24","upperLimit":"NA","value":"30.39"},{"groupId":"OG002","lowerLimit":"9.36","upperLimit":"34.23","value":"14.95"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"65"},{"groupId":"OG002","value":"72"}],"units":"Participants"}],"description":"The percentage of participants remaining alive. Median values are computed using Kaplan-Meier method","dispersionType":"95% Confidence Interval","groups":[{"description":"3mg/kg of nivolumab","id":"OG000","title":"Nivolumab Monotherapy (Expansion)"},{"description":"3 mg/kg of nivolumab and\n\n1 mg/kg of ipilimumab Q3W for 4 doses, followed by nivolumab alone at 3 mg/kg Q2W","id":"OG001","title":"Nivolumab + Ipilimumab"},{"description":"3 mg/kg of nivolumab Q2W + 3 mg/kg of lirilumab Q4W","id":"OG002","title":"Nivolumab + Lirilumab"}],"paramType":"MEDIAN","populationDescription":"All Treated Participants with available measurements","reportingStatus":"POSTED","timeFrame":"Nivo Mono: approximately up to 6 years and 9 months Nivo Ipi: approximately up to3 years Nivo Liri: approximately up to 4 years 1 month","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}